day 1 agenda

7th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
on Sep 07-08, 2026 at Paris, France
Day -1(Sep 07, 2026)
Meeting Hall: Paris 1
Registrations Open(08:30-08:50)

Moderator
Meagan J McManus, USA
Welocme Remarks(08:50:09:10)
Keynote Sessions
09:10- 09:40 KeynoteTalk: Genetic Therapies for APOE4-Associated Alzheimer’s Diseases
Ronald Crystal,Weill Cornell Medicine,USA
09:40-10:10 KeynoteTalk: ACE-dependent Alzheimer’s disease (AD)
Sergei M. Danilov,University of Illinois,USA
10:10-10:40 KeynoteTalk: Glomerular (mesangial) amyloidogenesis in AL (light chain-associated) amyloidosis: Translational studies with implications for further treatment modalities. Similarities with amyloid formation in Alzheimer disease
Guillermo A. Herrera,University of South Alabama,USA
Group Photo & Refreshment Break (10:40-11:00)
Session Chairs
Ronald G. Crystal, USA & Guillermo A. Herrera, USA
Technical session-I
Advances in Alzheimer’s and Dementia Research &
Neurodegenerative Diseases
11:00-11:20 Relationships among tau, amyloid, neuroinflammation, NMDA receptors and cognitive performance are strongly modulated by sex
Anat Biegon, University of Uppsala, Sweden
11:20-11:40 Moderate-Severe Traumatic Brain Injury May Cause Neurodegeneration in the Early and Late Chronic Stages of Injury
Robin Green,University of Toronto, Canada
11:40-12:00 The Enigma of Brain Iron: From Brain Iron Overload to Functional Iron Deficiency in Neurodegenerative Diseases
Levi Sonia,University Vita-Salute San Raffaele, Italy
12:00-12:20 Intermittent hypoxia training attenuates brain atrophy in elderly adultswith mild cognitive impairment
Xiangrong Shi, University of North Texas Health Science Centre, USA
12:20-12:40 Nonhuman Primate Models of Alzheimer’s Disease And Parkinson’sDisease Co-pathologies
Jeffrey H. Kordower, Arizona State University, USA
12:40-13:00 Imaging oxidative stress in neurodegenerative disorders with Positron Emission Tomography with [18F]ROStrace
Robert H. Mach,University of Pennsylvania, USA
13:00-13:20 Beyond Plaques and Tangles: Visualizing Early Oxidative Stress in Alzheimer's Disease via a Novel Radiotracer
Meagan J McManus,University of Arizona,USA
Lunch Break @ Restaurant (13:20-14:10)
Session Chair
Ebrahim Zandi, USA
Technical session-II
Vascular Dementia, Aging and Dementia, Risk reduction and prevention
14:10-14:40 Plenary Talk: Digital Twins in Clinical Trials for Alzheimer’s Disease
Irfan Chaudhuri, Harvard University, USA
14:40-15:00 The Traumatic brain injury and the risk of dementia
Wendy Lin, University of British Columbia, Canada
15:00-15:20 Arterial Tortuosity as a Marker of Cerebrovascular Aging and Dementia Risk
Yulin Ge, NYU Grossman School of Medicine, USA
15:20-15:40 Stepwise identification of prodromal dementia: testing a practical model for primary care
Boaz Levy, University of Massachusetts Boston, USA
15:40-16:00 Involvement of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in the Pathogenesis of Neurodegeneration
Xue-Ying He & Song-Yu Yang, NYS Institute for Basic Research in Developmental Disabilities, USA
PP-1 PASSCOG: Early Diagnosis of Alzheimer's Disease in Outpatient Settings
Blanchard Apolline & Gagliardi Geoffroy, Aloïs Association, France
Refreshment Break(16:20-16:30)
Day-1 Concludes

day 2 agenda

Day -2(Sep 08, 2026)
Meeting Hall: Paris 1
Registrations Open(08:30-08:50)
Moderator
TBA
Welocme Remarks(08:50:09:00)
Keynote Sessions
09:00-09:30 KeynoteTalk: GABA-A receptor modulating steroids enhance dementia, but antagonists inhibit inflammation and improve memory
Torbjörn Bäckström, Umeå University, Sweden
09:30-10:00 KeynoteTalk: Acetylcholinesterase inhibitors have anti- neurodegenerative benefits, but high-level CNS-selective acetylcholinesterase inhibition is needed for delaying the onset or preventing Alzheimer’s dementia
Donald E. Moss, University of Texas at El Paso, USA
10:00-10:30 KeynoteTalk: Cortical neuron dysfunction in AD brain at early-stage without beta-amyloid aggregation
Xiu-Ti Hu, Rush University Medical Center, USA
Group Photo & Refreshment Break (10:30-10:50)
Session Chairs
Xiu-Ti Hu, USA & Donald E. Moss, USA
Technical session-III
Biomarkers for AD and Dementia, Basic and Translational Research
&
Genetics in Alzheimer’s and Dementia, Molecular and Cell Biology,
Data Science and Artificial Intelligence
10:50-11:10 Long read sequencing in alzheimer’s disease and cerebral amyloid angiopathy
Amanda J. Myers, University of Miami, USA
11:10-11:30 From Cost-Effective Plasma Biomarker Quantification to Cross-Cohort Machine Learning Translation in Alzheimer’s Disease
Ebrahim Zandi, University of Southern California, USA
11:30-11:50 Towards a panel of seed amplification assays for the detection of protein
pathologies in the CSF of living patients with dementia
Magnus Macleod, University College London, United Kingdom
11:50-12:10 Exploring the role of Aβ-induced membrane damage in tau pathology
Katherine R. Sadleir, Northwestern University, USA
12:10-12:30 Development and Validation of Patient and Caregiver-Reported Outcome Measures for Alzheimer’s Disease, Mild Cognitive Impairment, and Dementia: The CI-HI & CICR-HI
Charlotte Engebrecht, University of Rochester Center for Health + Technology, USA
12:30-12:50 Transcranial Pulse Stimulation for early dementia: A Randomized, Sham-Controlled Safety and Efficacy Study
Francesca Pistoia, University of L'Aquila, Italy
12:50-13:10 Personalizing Repetitive TMS in Major Depressive Disorder: An EEG?Based dlPFC Sensitivity Index Predicts Clinical and Cognitive Outcomes
Li Wan, Anhui Medical University, USA
Lunch Break @ Restaurant (13:10-14:00)

posters agenda

Day -1(Sep 07, 2026)
 Virtual Program followed by CET(Paris Time)
13:10-13:30 Keynote Talk: Systems Thinking
Michael Fossel, Michigan State University, USA
13:30-13:50 The importance of social relationships in place in Alzheimer’s Disease
George Rook, a person living with dementia and co-researcher on several projects, USA
13:50-14:20  Establishing two-tier cutoffs for ptau217/A42 ratio in plasma for detection of Alzheimers disease pathology
Leslie M Shaw, University of Pennsylvania, USA
14:20-14:40 Keynote Talk: Elovanoids: linking nutrition to neuroprotection
Nicolas G. Bazan,Neuroscience Center of Excellence, USA
14:40-15:00 Methionine-sulfoxide based active immunization against Alzheimer’s disease
Jackob Moskovitz, University of Kansas, USA
15:00-15:20  Spiritual Fitness: The New Dimension In Alzheimer’s Disease Prevention
Eve Adler, Alzheimer's Research and Prevention Foundation, USA
15:20-15:40 Alzheimer’s disease: Amyloid beta switch from physiology to pathology and novel prevention and treatment approaches
Yuri Lyubchenko, University of Nebraska Medical Center, USA
15:40-16:00  From amyloid plaques to tau neurofibrillary tangles:
Connecting the dots in Alzheimer’s disease through GPC4
Brandon B. Holmes, University of California, USA
16:00-16:20 Treatment of bioenergetic and redox impairment in neurons promotes clearance of Aβ and tau aggregates, lowers oxidative nitration and promotes synapse formation 
Gregory J. Brewer, University of Califormia, USA
16:20-16:40  Air pollution risk of Alzheimer in a mouse model of amyloidogenesis
 is attenuated by modulation of gamma-secretase
Caleb E Finch, University of Southern California, USA
16:40-17:00 Combination treatment targeting upstream mechanisms of Alzheimer’s disease reduces biomarkers of disease and promotes synapse formation
Svara Shah, University of California Irvine, USA
Day-1 Concludes
   
Day -2(Sep 08, 2026)
 Virtual Program followed by CET(Paris Time)
08:30-08:50 6-microRNA panel predicts amyloid- β status in cognitively normal older adults
Joanna M. Williams, University of Otago, NewZealand
08:50-09:10 Cultural Perspectives on Virtual delivery of Cognitive Stimulation Therapy for M?ori with Dementia (vCST-M?ori)
Tai Kake, University of Auckland, NewZealand
09:10-09:30 The therapeutic potential of medicinal cannabis for neurodegenerative diseases – a preclinical perspective
Tim Karl, Western Sydney University, Australia
09:30-09:50 Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a
Kazumi Saikusa, National Metrology Institute of Japan (NMIJ), Japan
09:50-10:20 Keynote Talk: NAP, the investigational drug davunetide, from laboratory discovery to sex-specific cognitive protection in clinical trials
Illana Gozes, Tel Aviv University, Israel
10:20-10:40 Revitalizing Mitochondria against Alzheimer’s disease: The Synergistic Effects of a Nutraceutical Combination with urolithin A
Dona Pamoda W. Jayatunga, University of Sri Jayewardenepura, Sri Lanka
10:40-11:00 Early Linguistic Indicators and Language-Focused Therapies in Alzheimer’s Disease
Erika Smeriglio, University of Messina, Italy
11:00-11:20 Insights into Alzheimer’s Disease from Drosophila Models: Lessons Learned and Future Directions
Ann-Christin Brorsson, Linköping University, Sweden
11:20-11:50 Keynote Talk: Restoring neuronal function by restoring the septin cytoskeleton
Gerard Griffioen, remynd, Belgium
11:50-12:10 Huntingtin’s N17 region: Post-translational modifications as modulators of protein self-association and membrane interaction
Mariana Gallo, University of Parma, Italy
12:10-12:30 Selective manipulation of aging as a novel treatment for neurodegenerative disorders
Ehud Cohen, The Hebrew University School of Medicine, Israel
12:30-12:50 ‘This Is a Completely Changed Landscape’: Older Men’s Experiences of Caring for a Spouse with Dementia
Olga Asrun Stefansdottir, University of Akureyri, Iceland
12:50-13:10 AI-Driven Insights from Single-Cell Transcriptomics in Alzheimer’s Disease: Emerging Biomarkers and Therapeutic Targets
Prachi Srivastava, Amity University, India
13:10-13:30 Correction of the APP London (V717I) mutation using
an optimized prime editing system
Jacques P. Tremblay, Université Laval, Canada
13:30-13:50  Non-catalyzed covalent dimerization of amyloid β and implications for Alzheimer’s disease
Suren A. Tatulian, University of Central Florida, USA
13:50-14:10  Identification of novel shared antibodies and infectious disease associations in Alzheimer’s disease
Mark Hicar, University at Buffalo, USA
14:10-14:30 Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide
Ken Teter, University of Central Florida, USA
14:30-14:50  Molecular Mechanisms Underlying the Inverse Roles of Heme Function in Lung Cancer and Alzheimer’s Disease 
Li Zhang, Download